Personality, symptom, and demographic correlates of perceived efficacy of selective serotonin reuptake inhibitor monotherapy among current users with low mood: A data-driven approach

J Affect Disord. 2021 Dec 1:295:1122-1130. doi: 10.1016/j.jad.2021.08.088. Epub 2021 Sep 3.

Abstract

Background: Selective serotonin reuptake inhibitors (SSRIs) are often the first-line treatment option for depressive symptoms, however their efficacy varies across patients. Identifying predictors of response to SSRIs could facilitate personalised treatment of depression and improve treatment outcomes. The aim of this study was to develop a data-driven formulation of demographic, personality, and symptom-level factors associated with subjective response to SSRI treatment.

Methods: Participants were recruited online and data were collected retrospectively through an extensive digital mental health questionnaire. Extreme gradient boosting classification with nested cross-validation was used to identify factors distinguishing between individuals with low (n=37) and high (n=111) perceived benefit from SSRI treatment.

Results: The algorithm demonstrated a good predictive performance (test AUC=.88±.07). Positive affectivity was the strongest predictor of response to SSRIs and a major confounder of the remaining associations. After controlling for positive affectivity, as well as current wellbeing, severity of current depressive symptoms, and multicollinearity, only low positive affectivity, chronic pain, sleep problems, and unemployment remained significantly associated with diminished subjective response to SSRIs.

Limitations: This was an exploratory analysis of data collected at a single time point, for a study which had a different primary aim. Therefore, the results may not reflect causal relationships, and require validation in future prospective studies. Furthermore, the data were self-reported by internet users, which could affect integrity of the dataset and limit generalisability of the results.

Conclusions: Our findings suggest that demographic, personality, and symptom data may offer a potential cost-effective and efficient framework for SSRI treatment outcome prediction.

Keywords: Antidepressant; Classification; Extreme gradient boosting; Personalised healthcare; Predictive modelling; Treatment response.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Demography
  • Humans
  • Personality
  • Personality Disorders*
  • Retrospective Studies
  • Selective Serotonin Reuptake Inhibitors* / therapeutic use

Substances

  • Serotonin Uptake Inhibitors